ARCT News and Press, Arcturus Therapeutics Ltd. From 12/16/21

Arcturus Therapeutics (NASDAQ: ARCT) , which focuses on clinical-stage messenger RNA (mRNA) medicines, saw its shares rise 16% on Thursday. The stock closed at $35.52 on Wednesday, then opened at $38 today and rose to as high as $41.15 by midmorning. The stock has a 52-week high of ...

Arcturus Therapeutics (ARCT +13.3%) has added more than a tenth in value to record its sharpest intraday gain in four months after announcing preliminary data from its ongoing booster studies for messenger-RNA-based COVID-19 vaccine candidates, ARCT-154 and ARCT-165. In the booster cohort of ...

Gainers: Adagio Therapeutics (NASDAQ:ADGI) +68%, Calliditas Therapeutics (NASDAQ:CALT) +28%, Assertio (NASDAQ:ASRT) +17%, Aptose Biosciences (NASDAQ:APTO) +16%, Arcturus Therapeutics (NASDAQ:ARCT) +15%. Losers: uniQure (NASDAQ:QURE) -25%, Regi...

Preliminary data from ongoing clinical booster study of ARCT-154 (5 mcg) shows a 50-fold increase in neutralizing antibody geometric mean concentration against SARS-CoV-2 using a validated pseudovirus microneutralization (MNT) assay Additional data shows activity against sever...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Arcturus develops mRNA vaccines for covid-19. Other bigger players made the company almost irrelevant. Emerging variants of concern just may give the company a reason to exist. For further details see: Arcturus: Emerging Covid Variants May Provide A Raison D'êTre

Direxion Shares has launched the Direxion Nanotechnology ETF (NYSEARCA:TYNE), which provides exposure to stocks involved in the creation and or manipulation of matter at the molecular level. "Investors continue to seek exposure to disruptive industries, but one important area they may not yet...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2021 Earnings Conference Call November 8, 2021, 4:30 PM ET Company Participants Joseph Payne – President and CEO Deepankar Roy – Senior Director of Investor Relations Andy Sassine – CFO Pad Chivukula – CSO and COO Steve...

Arcturus Therapeutics (NASDAQ:ARCT): Q3 GAAP EPS of -$2.05 misses by $0.72. Revenue of $2.44M (+6.1% Y/Y) misses by $16.76M. Shares +2%. Press Release For further details see: Arcturus Therapeutics EPS misses by $0.72, misses on revenue